91103-37-6

Basic information

• Product Name: (S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate
• Synonyms: (S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate;CarbaMic acid, [(1S)-1-(hydroxyMethyl)-2-propenyl]-, 1,1-diMethylethylester;tert-butyl (S)-(1-hydroxybut-3-en-2-yl)carbamate;(s)-2-(boc-amino)-2-vinyl-ethanol
• CAS NO: 91103-37-6
• Molecular Formula: C₉H₁₇NO₃
• Molecular Weight: 187.23618
• Mol File: 91103-37-6.mol
• Article Data: 23

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate(91103-37-6)
• EPA Substance Registry System: (S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate(91103-37-6)

Safety Data

• Hazardous Substances Data: 91103-37-6(Hazardous Substances Data)

Usage

General Description

(S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate is a chemical compound with the molecular formula C10H19NO3. It is a carbamate derivative that contains a tert-butyl group and a hydroxybut-3-en-2-yl group. (S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate is commonly used as a reagent in organic synthesis for the protection of primary amines, and it can act as a precursor for the synthesis of other organic compounds. It is a white solid that is stable under normal conditions, and it is soluble in organic solvents such as dichloromethane and ethyl acetate. Overall, (S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate has various applications in chemical synthesis and is an important building block for the preparation of complex organic molecules.

Upstream product

• 913344-40-8 tert-butyl N-formyl carbamate 
• 318469-73-7 (2E)-4-hydroxybut-2-en-1-yl methyl carbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 174810-05-0 (-)-2-[(1S)-(hydroxymethyl)prop-2-enyl]-1H-isoindole-1,3-(2H)-dione 
• 88000-67-3 tert-butyl benzoylimidocarboxylate 
• 95715-87-0 (R)-3-tert-butoxycarbonyl-4-formyl-2,2-dimethyloxazolidine 
• 117609-25-3 (S)-(+)-2-amino-1-butanol 
• 930-22-3 epoxybutene 
• 33900-24-2 N-(tert-butoxycarbonyl)-L-methionine methyl ester 
• 451502-80-0 ethyl (2Z)-4-[(p-methoxyanilino)carbonyloxy]-2-butenyl carbonate 
• 142673-25-4 (4S)-4-ethenyl-1,3-oxazolidin-2-one 
• 115148-32-8 (S)-3-(4-methoxyphenyl)-4-vinyloxazolidin-2-one 
• 51372-93-1 (S)-tert-butyl (1-hydroxy-4-(methylthio)butan-2-yl)carbamate 
• 2488-15-5 N-tert-butoxycarbonyl-L-methionine 

Downstream Products

• 133625-87-3 tert-butyl (4S)-2,2-dimethyl-4-vinyl-1,3-oxazolidine-3-carboxylate 
• 917365-73-2 C₃₄H₃₅BrN₄O₁₀S₂ 
• 1315454-60-4 C₁₇H₂₅NO₅ 
• 106074-85-5 (2R,3R)-2-(tert-butoxycarbonyl)amino-3-(tetrahydropyranyl)oxy-4-<4-(tert-butyldimethylsilyl)oxy>phenylbutyl acetate 
• 104197-63-9 (2S,3R)-2-(tert-butoxycarbonyl)amino-3-(tetrahydropyranyl)oxy-4-<4-(tert-butyldimethylsilyl)oxy>phenylbutyric acid 2-pyridyl thiolester 
• 106074-86-6 (2R,3R)-2-(tert-butoxycarbonyl)amino-3-(tetrahydropyranyl)oxy-4-<4-(tert-butyldimethylsilyl)oxy>phenylbutanol 
• 104241-27-2 (2R,3R)-2-(tert-butoxycarbonyl)amino-3-hydroxy-4-<4-(tert-butyldimethylsilyl)oxy>phenylbutyl acetate 

Relevant articles and documents

Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors

An alternative medicinal chemistry approach was conducted on Bruton's tyrosine kinase (BTK) inhibitor 1 (ibrutinib) by merging the pyrazolo[3,4-d]pyrimidine component into a tricyclic skeleton. Two types of compounds were prepared, and their biochemical activities on BTK as well as stereochemistry effects were determined. Structural optimization focusing on the reactive binding group to BTK Cys481 and on the metabolic site guided by metabolic study were conducted. 7S was identified as the most potent showing an IC50 value of 0.4 nM against BTK and 16 nM against BTK-dependent TMD8 cells. Compared to 1, 7S was slightly more selective with strong inhibition on the B-cell receptor signaling pathway. In a TMD8 cell-derived animal xenograft model, 7S showed a relative tumor volume of 5.3 at 15 mg/kg QD dosage that was more efficacious than 1 (RTV 6.6) at a higher dose of 25 mg/kg QD. All these results suggest 7S as a new BTK inhibitor worthy of further profiling.

MACROCYCLIC LRRK2 KINASE INHIBITORS

The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.

SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS

This application relates to methods of increasing survival or progression-free survival in a patient with a solid tumor, wherein the patient has an elevated serum concentration of C-reactive protein (CRP), by administering a JAK inhibitor or an inhibitor of IL-6 signaling to the patient, as well as methods of predicting survival benefit in these patients from such therapy.